UV‐Visible and Electrochemical Monitoring of Carbon Monoxide Release by Donor Complexes to Myoglobin Solutions and to Electrodes Modified with Films Containing Hemin

This study reports on the evaluation of the CO donating behavior of tricarbonyl dichloro ruthenium(II) dimer ([Ru(CO)₃Cl₂]₂) and 1,3‐dimethoxyphenyl tricarbonyl chromium (C₆H₃(MeO)₂Cr(CO)₃) complex by UV‐visible technique and electrochemical technique. The CO release was monitored by following the modifications of the UV‐visible features of MbFe(II) in phosphate buffer solution and the redox features of reduced Hemin, HmFe(II), confined at the surface of a vitreous carbon electrode. In the latter case, the interaction between the hemin‐modified electrode and the released CO was seen through the observation of an increase of the reduction current related to the Fe^III/Fe^II redox process of the immobilized porphyrin. While the ruthenium‐based complex, ([Ru(CO)₃Cl₂]₂), depended on the presence of Fe(II) species to release CO, it was found that the chromium‐based complex released spontaneously CO. This was facilitated by illuminating and/or simple stirring of the solution containing the complex.     

Copolyesteramides—II. Anionic copolymers of ε-caprolactam with ε-caprolactone. Preparation and general properties

The N-sodiocaprolactam-catalysed anionic polymerisation of ε-caprolactam is activated by ε-caprolactone which itself acts as a comonomer, yielding copolyesteramides. At lower temperatures and lower catalyst concentrations, copolymerisation of the lactone is favoured over that of lactam; higher temperatures, higher catalyst concentrations and longer reaction times cause a more equal incorporation of the two comonomers giving products with molecular weights in the order of 10⁴ and with NH(CH₂)₅CO and O(CH₂)₅CO unit contents approximating to those in the reactant feeds. The T_g's of the products lie between those of the homopolymer extremes but the T_m vs composition relationship displays a shallow eutectic minimum at ca 20% NH(CH₂)₅CO group content and, for given NH(CH₂)₅CO group contents, is sensitive to changes in the technique of copolymerisation. Alternatingly-sequenced NH(CH₂)₅CO/O(CH₂)₅CO copolymers prepared by polycondensation also differ from anionic copolymers of similar sub-unit stoichiometry. The property differences imply differences of chain-sequential order and hence complexity in the mechanism of the anionic copolymerisation.     

Spatiotemporally controlled O2 and singlet oxygen self-sufficient nanophotosensitizers enable the in vivo high-yield synthesis of drugs and efficient hypoxic tumor therapy

Carrying out the in vivo syntheses of drugs toxic to tumors based on the specific features of the tumor microenvironment is critical for ensuring specific antitumor efficacy. However, achieving in situ high-yield synthetic toxic drugs from non-toxic agents and reducing their drug resistance in hypoxic tumors remain challenges. Herein we created a tumor-microenvironment-responsive porous Pt/Pt(iv) methylene blue coordination polymer nanoshuttle (Pt/PtMBCPNS) photosensitizer with spatiotemporally controlled O₂ and singlet oxygen (¹O₂) self-sufficient for the in vivo high-yield synthesis of drugs and efficient hypoxic tumor therapy. After being endocytosed, the nanophotosensitizer as a cascade catalyst was observed to effectively catalyze the conversion of endogenous H₂O₂ to O₂, and was hence found to play a dual role in the enhanced tumor therapy. PtMBCPNSs, upon being irradiated with red light, efficiently converted O₂ into ¹O₂. Subsequently, ¹O₂ oxidized non-toxic 1,5-dihydroxynaphthalene to form the anticancer agent juglone with a high yield. In addition, O₂ was found to be able to improve the hypoxic microenvironment without light irradiation, thus enhancing the antitumor efficacy of the produced drugs and reducing drug resistance. As a result, by enhancing the synergistic effect of the treatment, this nanophotosensitizer significantly inhibited the growth of tumors and avoided damage to normal tissues/organs. Collectively, this work highlights a robust nanoplatform with the spatiotemporally controlled in vivo high-yield synthesis of drugs and generation of O₂ to help overcome the current limitations of chemical-based therapies against hypoxic tumors.

A porous photosensitizer displaying catalase-like activity and drug synthesis ability was synthesized for the synergistic chemo-photodynamic therapy, opening new promising ways for carrying out the precise cooperative treatment of hypoxic tumors.     

Preparation and preliminary evaluation of a tris-metronidazole-<Superscript>99m</Superscript>Tc(CO)<Subscript>3</Subscript> complex for targeting tumor hypoxia

Conventional ^99mTc-radiopharmaceuticals for the detection of tumor hypoxia generally possess a single nitroimidazole moiety. Herein, we report the synthesis and evaluation of a ^99mTc-complex with three-nitroimidazole moieties in an attempt to improve hypoxic cell detection. Isocyanide derivative of metronidazole (MetroNC) was synthesized and subsequently radiolabeled with [^99mTc(CO)₃(H₂O)₃]⁺ precursor complex, wherein the three labile water molecules were replaced with MetroNC ligand to form a pseudo-octahedral [^99mTc(CO)₃(MetroNC)₃]⁺ complex. Analysis of corresponding Re(CO)₃-analog prepared in macroscopic scale confirmed the formation of expected complex. Cyclic voltammetric studies of [Re(CO)₃(MetroNC)₃]⁺ complex showed no significant change in single-electron reduction potential (SERP) of MetroNC ligand (??0.96 V) upon forming the [Re(CO)₃(MetroNC)₃]⁺ complex (??0.90 V). In vitro studies in Chinese hamster ovary (CHO) cells showed three-fold preferential accumulation of [^99mTc(CO)₃(MetroNC)₃]⁺ complex in hypoxic cells over normoxic cells. Biodistribution studies of [^99mTc(CO)₃(MetroNC)₃]⁺ complex in Swiss mice bearing fibrosarcoma tumor showed tumor uptake and steady retention till 60 min post injection. Present study constitutes a novel design approach towards development of a ^99mTc-radiopharmaceutical for hypoxia imaging application, which could be extended to other potential nitroimidazole ligands.     

A convenient stereoselective synthesis of cationic (η3-allyl)iron tetracarbonyl complexes

Allylic alcohols have been found to react with Fe₂(CO)₉ in ether to afford after addition of HBF₄/acetic anhydride, the corresponding (η³-allyl)Fe(CO)₄⁺BF₄^?- species (I) in moderate to good yields. The geometry of the starting alcohol is retained in the product complex; thus E-crotyl and -cinnamyl alcohols led to anti-substituted complexes, whereas the corresponding Z-alcohols produced syn-complexes.     

The reaction of bis[tricarbonyl(triphenylphosphine)iridium],Ir2(CO)6(PPH3)2, with diazonium salts

The reaction of Ir₂(CO)₆(PPh₃)₂ with p-substituted aryldiazoniurn salts gives the o-metalated complexes [Ir(CO)₂(NHNC₆H₃R) (PPh₃)]₂²⁺ 2BF₄^?. These react with KOH in ethanol to give the deprotonated derivatives, and with halogens to give halogenated derivatives by cleavage of the carbonmetal bond.     

CO/light dual-activatable Ru(ii)-conjugated oligomer agent for lysosome-targeted multimodal cancer therapeutics

Stimuli-activatable and subcellular organelle-targeted agents with multimodal therapeutics are urgently desired for highly precise and effective cancer treatment. Herein, a CO/light dual-activatable Ru(ii)-oligo-(thiophene ethynylene) (Ru-OTE) for lysosome-targeted cancer therapy is reported. Ru-OTE is prepared via the coordination-driven self-assembly of a cationic conjugated oligomer (OTE-BN) ligand and a Ru(ii) center. Upon the dual-triggering of internal gaseous signaling molecular CO and external light, Ru-OTE undergoes ligand substitution and releases OTE-BN followed by dramatic fluorescence recovery, which could be used for monitoring drug delivery and imaging guided anticancer treatments. The released OTE-BN selectively accumulates in lysosomes, physically breaking their integrity. Then, the generated cytotoxic singlet oxygen (¹O₂) causes severe lysosome damage, thus leading to cancer cell death via photodynamic therapy (PDT). Meanwhile, the release of the Ru(ii) core also suppresses cancer cell growth as an anticancer metal drug. Its significant anticancer effect is realized via the multimodal therapeutics of physical disruption/PDT/chemotherapy. Importantly, Ru-OTE can be directly photo-activated using a two-photon laser (800 nm) for efficient drug release and near-infrared PDT. Furthermore, Ru-OTE with light irradiation inhibits tumor growth in an MDA-MB-231 breast tumor model with negligible side effects. This study demonstrates that the development of an activatable Ru(ii)-conjugated oligomer potential drug provides a new strategy for effective subcellular organelle-targeted multimodal cancer therapeutics.

The anticancer therapeutics of lysosome disruption/PDT/chemotherapy based on Ru-OTE complex was achieved, which provides a new strategy for developing multimodal and effective stimuli-activatable subcellular organelle-targeted cancer therapeutics.     

Protonation of Cp(CO)(PPh3) RuCCPh: Formation of cationnic phenylacetylene and phenylvinylidene complexes and subsequent reaction with ethylene oxide to form the net [2 + 3] cycloadduct [Cp(CO)(PPH3)Ru=CCH(Ph)CH2CH2O]+

Protonation of the alkynyl complex Cp(CO)(PPh₃)RuCCPh (1) at low temperature affords quantitatively the vinylidened complex [Cp(CO)(PPh₃)RuCCH(Ph)]⁺ (3), which upon warming to room temperature forms an equilibrium with the η²-phenylacetylene complex [Cp(CO)(PPh₃)Ru(η²-HCCPh)]⁺ (4), with the latter predominating. Subsequent reaction with ethylene oxide yields the cyclic oxacarbene complex [Cp(CO)(PPH₃)Ru=CCH(Ph)CH₂CH₂O]⁺ (5), which can be regarded as the result of a net [3+2] cycloaddition reaction between 3 and ethylene oxide. Depronation of 5 affords teh corresponding neutral cyclic vinyl complex [Cp(CO)(PPH₃)RuC=C(Ph)CH₂CH₂O]⁺ (6), which can in turn be protonated to regenerate 5 in a diastereoselective manner. The structures of complexes 5 and 6 were determined by X-ray crystallography.     

13C and 19F NMR substituent chemical shifts (SCS) of some bridgehead-substituted phenyl- and fluorophenylbicyclo [2.2.2] octyltricarbonylchromium(O) derivatives: nature of aryl 19F NMR polar field effects in the Cr(CO)3-complexed benzene ring system

A number of Cr(CO)₃ complexes of bridgehead-substituted phenylbicyclo[2.2.2]octanes and (m- and p-)fluoropheylbicyclo[2.2.2]octanes have been synthesized and their ¹³C and ¹⁹F NMR spectra have been recorded, respectively. The substituent chemical shifts (SCS) of these stereochemically well-defined model systems permit an unambiguous evaluation of polar factors governing ¹³C and ¹⁹F SCS in arene-Cr(CO)₃ complexes. The dual nature of ¹⁹F NMR polar field effects is reaffirmed and the coefficient (A) of the Buckingham equation for linear electric field effects on C(sp²)F bonds in fluoroarene-Cr(CO)₃ complexes has been calculated. A re-examination and re-interpretation of the ¹⁹F chemical shifts of m- and p-substituted fluorophenyltricarbonylchromium derivatives is also reported. New substituent parameters (σ_I and σ^o_R) for C₆H₅ · Cr(CO)₃ as a substituent in the neutral ground state arepresented.     

Tumor microenvironment-responsive MnSiO3-Pt@BSA-Ce6 nanoplatform for synergistic catalysis-enhanced sonodynamic and chemodynamic cancer therapy

Compared with traditional photodynamic therapy （PDT）,ultrasound （US） triggered sonodynamic therapy （SDT） has a wide application prospect in tumor therapy because of its deeper penetration depth.Herein,a novel MnSiO₃-Pt （MP） nanocomposite composed of Mn Si O₃nanosphere and noble metallic Pt was successfully constructed.After modification with bovine serum albumin （BSA） and chlorine e6 （Ce6）,the multifunctional nanoplatform Mn Si O₃-Pt@BSA-Ce6 （MPBC） realized the m...     

Metallacyclic complexes with ortho-stannylated triphenylphosphine ligands, LnOs(κ(Sn,P)-SnMe2C6H4PPh2), derived from thermal reactions of the five-coordinate complex, Os(SnMe3)Cl(CO)(PPh3)2

Heating the five-coordinate trimethylstannyl complex, Os(SnMe₃)Cl(CO)(PPh₃)₂, in solution with triphenylphosphine induces an ortho-stannylation of one phenyl group of a triphenylphosphine ligand and an ortho-metallation of another triphenylphosphine ligand, to produce the metallacyclic complexes, Os(κ²(Sn,P)-SnMeClC₆H₄PPh₂)(κ²(C,P)-C₆H₄PPh₂)(CO)(PPh₃) (1) and Os(κ²(Sn,P)-SnMe₂C₆H₄PPh₂)(κ²(C,P)-C₆H₄PPh₂)(CO)(PPh₃) (2), suggesting the possible intermediacy of a complex with a coordinated stannylene ligand. Spectroscopic data indicate that only one diastereomer of 1 is formed and crystal structure determination of 1 reveals that this is the diastereomer with chloride directed towards the CO ligand. Complex 2 is converted to 1 through a redistribution reaction with SnMe₂Cl₂. Heating the six-coordinate trimethylstannyl complex, Os(SnMe₃)Cl(CO)₂(PPh₃)₂, in solution produces the osmium(II) methyl complex, Os(Me)(SnMe₂Cl)(CO)₂(PPh₃)₂ (3), through an exchange of methyl and chloride groups on the tin and osmium. In this rearrangement, the relative locations of the two CO ligands and the two PPh₃ ligands remains unchanged. However, when the six-coordinate trimethylstannyl complex, Os(SnMe₃)Cl(CO)₂(PPh₃)₂ is heated under CO, the same exchange reaction is observed but the mono-triphenylphosphine, tricarbonyl complex, Os(Me)(SnMe₂Cl)(CO)₃(PPh₃) (4), is produced and here the SnMe₂Cl ligand is located trans to the PPh₃ ligand. Crystal structure determinations for 1, 2, 3, and 4 have been obtained.     

Metallacyclic complexes with ortho-silylated triphenylphosphine ligands, LnOs(κ(Si,P)-SiMe2C6H4PPh2), derived from thermal reactions of the coordinatively unsaturated trimethylsilyl, methyl complex, Os(SiMe3)(Me)(CO)(PPh3)2

Reaction between Os(SiCl₃)Cl(CO)(PPh₃)₂ and five equivalents of MeLi produces a colourless intermediate, tentatively formulated as the lithium salt of the six-coordinate, dimethyl, trimethylsilyl-containing complex anion, Li[Os(SiMe₃)(Me)₂(CO)(PPh₃)₂]. Reaction of this material with ethanol releases methane and gives the red, coordinatively unsaturated methyl, trimethylsilyl-containing complex, Os(SiMe₃)(Me)(CO)(PPh₃)₂ (1). An alternative synthesis of 1 is to add one equivalent of MeLi to Os(SiMe₃)Cl(CO)(PPh₃)₂, which in turn is obtained by adding three equivalents of MeLi to Os(SiCl₃)Cl(CO)(PPh₃)₂. Treatment of 1 with p-tolyl lithium, again gives a colourless intermediate which may be Li[Os(SiMe₃)(Me)(p-tolyl)(CO)(PPh₃)₂], and reaction with ethanol gives the red complex, Os(SiMe₃)(p-tolyl)(CO)(PPh₃)₂ (3). Complexes 1 and 3 are readily carbonylated to Os(SiMe₃)(Me)(CO)₂(PPh₃)₂ (2) and Os(SiMe₃)(p-tolyl)(CO)₂(PPh₃)₂ (4), respectively. Heating Os(SiMe₃)Cl(CO)(PPh₃)₂ in molten triphenylphosphine results only in loss of the trimethylsilyl ligand and formation of the previously known complex containing an ortho-metallated triphenylphosphine ligand, Os(κ²(C,P)-C₆H₄PPh₂)Cl(CO)(PPh₃)₂. In contrast, heating the five-coordinate osmium-methyl complex, Os(SiMe₃)(Me)(CO)(PPh₃)₂ (1), in the presence of triphenylphosphine results mainly, not in tetramethylsilane elimination, but in ortho-silylation as well as ortho-metallation of different triphenylphosphine ligands giving, Os(κ²(Si,P)-SiMe₂C₆H₄PPh₂)(κ²(C,P)-C₆H₄PPh₂)(CO)(PPh₃) (5). A byproduct of this reaction is the non-silicon containing di-ortho-metallated complex, Os(κ²(C,P)-C₆H₄PPh₂)₂(CO)(PPh₃) (6). A similar reaction occurs when Os(SiMe₃)(Me)(CO)(PPh₃)₂ (1) is heated in the presence of tri(N-pyrrolyl)phosphine producing Os(κ²(Si,P)-SiMe₂C₆H₄PPh₂)(κ²(C,P)-C₆H₄PPh₂)(CO)[P(NC₄H₄)₃] (7) but a better synthesis of 7 is to treat 5 directly with tri(N-pyrrolyl)phosphine. Heating the six-coordinate complex, Os(SiMe₃)(Me)(CO)₂(PPh₃)₂ (2), gives two complexes both containing ortho-metallated triphenylphosphine, one with loss of the trimethylsilyl ligand, giving the known complex, Os(κ²(C,P)-C₆H₄PPh₂)H(CO)₂(PPh₃), and the other with retention of the trimethylsilyl ligand, giving Os(SiMe₃)(κ²(C,P)-C₆H₄PPh₂)(CO)₂(PPh₃) (8). Crystal structure determinations for 5, 6, 7 and 8 have been obtained.     

Spontaneous CO Release from RuII(CO)2–Protein Complexes in Aqueous Solution,Cells, and Mice

We demonstrate that Ru^II(CO)₂–protein complexes, formed by the reaction of the hydrolytic decomposition products of [fac‐RuCl(κ²‐H₂NCH₂CO₂)(CO)₃] (CORM‐3) with histidine residues exposed on the surface of proteins, spontaneously release CO in aqueous solution, cells, and mice. CO release was detected by mass spectrometry (MS) and confocal microscopy using a CO‐responsive turn‐on fluorescent probe. These findings support our hypothesis that plasma proteins act as CO carriers after in vivo administration of CORM‐3. CO released from a synthetic bovine serum albumin (BSA)–Ru^II(CO)₂ complex leads to downregulation of the cytokines interleukin (IL)‐6, IL‐10, and tumor necrosis factor (TNF)‐α in cancer cells. Finally, administration of BSA–Ru^II(CO)₂ in mice bearing a colon carcinoma tumor results in enhanced CO accumulation at the tumor. Our data suggest the use of Ru^II(CO)₂–protein complexes as viable alternatives for the safe and spatially controlled delivery of therapeutic CO in vivo.     

Spontaneous CO Release from RuII(CO)2–Protein Complexes in Aqueous Solution,Cells, and Mice

We demonstrate that Ru^II(CO)₂–protein complexes, formed by the reaction of the hydrolytic decomposition products of [fac‐RuCl(κ²‐H₂NCH₂CO₂)(CO)₃] (CORM‐3) with histidine residues exposed on the surface of proteins, spontaneously release CO in aqueous solution, cells, and mice. CO release was detected by mass spectrometry (MS) and confocal microscopy using a CO‐responsive turn‐on fluorescent probe. These findings support our hypothesis that plasma proteins act as CO carriers after in vivo administration of CORM‐3. CO released from a synthetic bovine serum albumin (BSA)–Ru^II(CO)₂ complex leads to downregulation of the cytokines interleukin (IL)‐6, IL‐10, and tumor necrosis factor (TNF)‐α in cancer cells. Finally, administration of BSA–Ru^II(CO)₂ in mice bearing a colon carcinoma tumor results in enhanced CO accumulation at the tumor. Our data suggest the use of Ru^II(CO)₂–protein complexes as viable alternatives for the safe and spatially controlled delivery of therapeutic CO in vivo.     

Alkoxide attack at carbonyl and hydrosulphide attack at isocyanide in the mixed carbonyl-isocyanide cation [OsCl(CO)2(CNR)(PPh3)2]+. A new synthesis of π-bound isothiocyanate (RNCS) complexes

[OsCl(CO)₂(CNR)(PPh₃)₂]⁺ (R = p-tolyl) reacts with OMe^? to give OsCl(CO₂Me)(CO)(CNR)(PPh₃)₂ but reaction with SH^? produces the π-bound p-tolylisothiocyanate complex, Os(η²-SCNR)(CO)₂(PPh₃)₂, which can be protonated or methylated at N to yield complexes containing bidentate thiocarboxamido-ligands.     

A BODIPY-modified polymeric micelle for sustaining enhanced photodynamic therapy

Photodynamic therapy（PDT） has been gaining popularity in both scientific research and clinic applications due to its non-invasiveness and spatiotemporal targeting properties. Nevertheless, the local hypoxic microenvironment in tumor tissue impedes PDT universality. To overcome this drawback, a 2-pyridonebearing BODIPY photosensitizer was synthesized rationally and introduced to polyethyleneglycol-bpoly（aspartic acid） to form a photosensitizer-¹O₂ generation, storage/release...     

From straight chain to macrocyclic complexes containing mixed sulfur/nitrogen donors and coordinated 1,3-diynes

The acid-mediated reaction of [{Co₂(CO)₆(μ-η²-HOCH₂CC-)}₂] (1) with the meta- and para-substituted aminothiophenols, 3-NH₂-C₆H₄SH and 4-NH₂-C₆H₄SH, affords the straight chain species, [{Co₂(CO)₆(μ-η²-(3-NH₂-C₆H₄S)CH₂CC-)}₂] (2) and [{Co₂(CO)₆(μ-η²-(4-NH₂-C₆H₄S)CH₂CC-)}₂] (3), respectively. The molecular structure of 3 reveals the presence of two isomeric forms differing in the relative disposition of the S-aryl groups. Conversely, reaction of 1 with the ortho-substituted aminothiophenol, 2-NH₂-C₆H₄SH, furnishes the 10-membered macrocyclic species [{Co₂(CO)₆}₂{cyclo-μ-η²:μ-η²-CH₂C₂C₂CH₂SC₆H₃-NH-2}] (4) along with the linear chain complex [{Co₂(CO)₆(μ-η²-(2-NH₂-C₆H₄S)CH₂CC-)}₂] (5). On the other hand, treatment of 1 with the ortho-substituted mercaptopyridine, 2-SH-C₅H₄N, in the presence of HBF₄ gives the salt [{Co₂(CO)₆(μ-η²-(2-S-C₅H₄NH)CH₂CC-)}₂](BF₄)₂ (6a) in good yield; work-up in the presence of base affords the neutral complex [{Co₂(CO)₆(μ-η²-(2-S-C₅H₄N)CH₂CC-)}₂] (6b). Single crystal X-ray diffraction studies have been reported on 3-5 and 6a.     

Self-recognition by the iron chiral auxiliary [(η5-C5H5)Fe(CO)(PPh3] in the formation of (RR,SS)-[(η5-C5H5)FE(CO)(PPh3)COCH2]2CH2

Complete self-recognition of chirality is observed in the Michael addition of the enolate derived from R,S-[η⁵-C₅H₅Fe(CO)(PPh₃-COCH₃] to the acryloyl complex R,S-[(η⁵-C₅H₅Fe(CO)(PPh₃)-COCHCH₂)] to generate exclusively the single diastereoisomer of the glutaroyl complex RR,SS-[(η⁵-C₅H₅)Fe(CO)(PPh₃)COCH₂]₂CH₂.     

X-Ray-triggered Carbon Monoxide and Manganese Dioxide Generation based on Scintillating Nanoparticles for Cascade Cancer Radiosensitization

Carbon monoxide (CO) is an endogenous signaling molecule with broad therapeutic effects. Here, a multifunctional X-ray-triggered carbon monoxide (CO) and manganese dioxide (MnO₂) generation nanoplatform based on metal carbonyl and scintillating nanoparticles (SCNPs) is reported. Attributed to the radioluminescent characteristic of SCNPs, UV-responsive Mn₂(CO)₁₀ is not only indirectly activated to release CO by X-ray but can also be degraded into MnO₂. A high dose of CO can be used as a glycolytic inhibitor for tumor suppression; it will also sensitize tumor cells to radiotherapy. Meanwhile MnO₂, as the photolytic byproduct of Mn₂(CO)₁₀, has both glutathione (GSH) depletion and Fenton-like Mn²⁺ delivery properties to produce highly toxic hydroxyl radical (⋅OH) in tumors. Thus, this strategy can realize X-ray-activated CO release, GSH depletion, and ⋅OH generation for cascade cancer radiosensitization. Furthermore, X-ray-activated Mn²⁺ in vivo demonstrates an MRI contrast effect, making it a potential theranostic nanoplatform.     

Synthesis of the pentacarbonyl(chalcocarbonyl)chromium(0) complexes,Cr(CO)5(CX) (X = S,Se)

The arene complexes, (η⁶-C₆H₆)Cr(CO)₂(CX) (X = S, Se), react with excess CO gas under pressure in tetrahydrofuran at about 60° C to produce the Cr(CO)₅(CX) complexes in high yield. The IR and NMR (¹³C and ¹⁷O) spectra of these complexes are in complete accord with the expected C_4v molecular symmetry. Like the analogous W(CO)₅(CS) complex, both compounds react with cyclohexylamine to give Cr(CO)₅(CNC₆H₁₁). However, while W(CO)₅(CS) undergoes stereospecific CO substitution with halide ions (Y^? to form trans-[W(CO)₄(CS)Y]^?, the two chromium chalcocarbonyl complexes apparently undergo both CO and CX substitution to afford mixtures of [Cr(CO)₅Y]^? and trans-[Cr(CO)₄(CX)Y]^?.